The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Voznyuk I.A.

Zavadenko N.N.

Pirogov Russian National Research Medical University

Kamchatnov P.R.

Pirogov Russian National Research Medical University

Levin O.S.

Russian Medical Academy of Continuous Professional Education

Parfenov V.A.

Sechenov First Moscow State Medical University

Solovieva E.Yu.

Pirogov Russian National Research Medical University

Khasanova D.R.

Interregional Clinical and Diagnostic Center;
Kazan State Medical University

Results of the round table: modern approaches to drug therapy of cognitive impairment in cerebrovascular pathology

Authors:

Voznyuk I.A., Zavadenko N.N., Kamchatnov P.R., Levin O.S., Parfenov V.A., Solovieva E.Yu., Khasanova D.R.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(8): 147‑152

DOI: 10.17116/jnevro2021121081147

Read: 4163 times

Download PDF (RU)
Contact the author
Table of contents

RESULTS OF THE ROUND TABLE: MODERN APPROACHES TO DRUG THERAPY OF COGNITIVE IMPAIRMENT IN CEREBROVASCULAR PATHOLOGY
RESULTS OF THE ROUND TABLE: MODERN APPROACHES TO DRUG THERAPY OF COGNITIVE IMPAIRMENT IN CEREBROVASCULAR PATHOLOGY

To cite this article:

Voznyuk IA, Zavadenko NN, Kamchatnov PR, Levin OS, Parfenov VA, Solovieva EYu, Khasanova DR. Results of the round table: modern approaches to drug therapy of cognitive impairment in cerebrovascular pathology. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(8):147‑152. (In Russ.)
https://doi.org/10.17116/jnevro2021121081147

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Modern aspe­cts of chro­nic cere­bral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113
Gender aspe­cts of atte­ntion defi­cit hype­ractivity diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):70-75
The asso­ciation of NOS1AP gene poly­morphisms with the dura­tion of the QT inte­rval in patients with schi­zophrenia receiving anti­psychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104
Functional state of the kidneys in patients with various types of cere­brovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):105-111
Differential diagnosis of Alzheimer’s disease and vascular cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Inci­dence of diseases of the circulatory system in the working-age popu­lation of the Ural Fede­ral District in 2012—2022. Russian Journal of Preventive Medi­cine. 2025;(1):24-29
Prevalence of cere­brovascular diseases risk factors acco­rding to the cohort survey data in Bishkek, Kyrgyz Repu­blic. Russian Journal of Preventive Medi­cine. 2025;(3):34-39
Characteristics, treatment features and in-hospital mortality of patients with myocardial infa­rction over 75 years old in Russia acco­rding to the REGION-IM regi­stry. Russian Cardiology Bulletin. 2025;(1):22-38
Abstract:

On June 25—26, 2021, a round table was held in Kazan with the participation of leading neurologists of Russia, where the issues of treatment of patients with cognitive impairment due to cerebrovascular diseases were discussed. Cognitive disorders of vascular genesis (VCD) are widespread in the population, are a common cause of a decrease in the quality of life and restriction of daily activity. The cause of VCD is both acute and chronic cerebrovascular diseases. An effective way to prevent VCD is to control cardiovascular risk factors, ensure a sufficient level of cognitive and physical activity throughout life. The role of drug therapy, aimed, among other things, at normalizing metabolic processes in the brain, is extremely important. The data on the mechanisms of action of the new domestic drug prospecta, the results of its clinical trials in patients with VCD are presented.

Keywords:

cerebrovascular diseases
vascular cognitive disorders
therapy
prospecta

Authors:

Voznyuk I.A.

Zavadenko N.N.

Pirogov Russian National Research Medical University

Kamchatnov P.R.

Pirogov Russian National Research Medical University

Levin O.S.

Russian Medical Academy of Continuous Professional Education

Parfenov V.A.

Sechenov First Moscow State Medical University

Solovieva E.Yu.

Pirogov Russian National Research Medical University

Khasanova D.R.

Interregional Clinical and Diagnostic Center;
Kazan State Medical University

Received:

01.07.2021

Accepted:

17.07.2021

Close metadata

References:

  1. Gusev E.I., Bogolepova A.N. Kognitivnye narushenija pri cerebrovaskuljarnyh zabolevanijah. Moskva: MEDpress-inform. 2013;180. (in Russ.)
  2. Rehm J, Ferreira-Borges C. Risk factor policies, morbidity, and mortality in Russia. The Lancet. 2018;392:1094-5.  https://doi.org/10.1016/S0140-6736(18)32043-9
  3. GBD 2016 Stroke Collaborators Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;48:439−458. 
  4. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Stroke. 2011;42(9):2672-713.  https://doi.org/10.1161/STR.0b013e3182299496
  5. Wortmann M. Dementia: a global health priority — highlights from an ADI and World Health Organization report. Alzheimers Res Ther. 2012;4:40.  https://doi.org/10.1186/alzrt143
  6. Goodman RA, Lochner KA, Thambisetty M, Wingo TS, Posner SF, Ling SM. Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011—2013. Alzheimers Dement. 2017;13(1):28-37.  https://doi.org/10.1016/j.jalz.2016.04.002
  7. Rockwood K, Wentzel C, Hachinski V, Hogan DB, MacKnight C, McDowell I. Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology. 2000;54:447–451.  https://doi.org/10.1212/wnl.54.2.447
  8. Bogolepova AN. Osvedomlennost’ naselenija o probleme demencii. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2015;115(6):97-102. (In Russ.). https://doi.org/10.17116/jnevro20151156197-102
  9. Parfenov VA. Vascular cognitive impairment and chronic cerebral ischemia (dyscirculatory encephalopathy). Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3S):61-67. (In Russ.). https://doi.org/10.14412/2074-2711-2019-3S-61-67
  10. O’Brien JT, Erkinjuntti T, Reisberg B. Vascular cognitive impairment. Lancet Neurol. 2003;2:89-98.  https://doi.org/10.1016/S1474-4422(03)00305-3
  11. Sachdev P, Kalaria R, O’Brien J. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-18.  https://doi.org/10.1097/WAD.0000000000000034
  12. Iadecola C, Duering M, Hachinski V, Joutel A, Pendlebury ST, Schneider JA, Dichgans M. Vascular Cognitive Impairment and Dementia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019;73(25):3326-3344. https://doi.org/10.1016/j.jacc.2019.04.034
  13. Skrobot OA, Attems J, Esiri M, Hortobágyi T, Ironside JW, Kalaria RN, King A, Lammie GA, Mann D, Neal J, Ben-Shlomo Y, Kehoe PG, Love S. Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment. Brain. 2016;139(11):2957-2969. https://doi.org/10.1093/brain/aww214
  14. Kuźma E, Lourida I, Moore SF, Levine DA, Ukoumunne OC, Llewellyn DJ. Stroke and dementia risk: A systematic review and meta-analysis. Alzheimers Dement. 2018;14(11):1416-1426. https://doi.org/10.1016/j.jalz.2018.06.3061
  15. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8(11):1006-18.  https://doi.org/10.1016/S1474-4422(09)70236-4
  16. Sexton E, McLoughlin A, Williams DJ, et al. Systematic review and meta-analysis of the prevalence of cognitive impairment no dementia in the first year post-stroke. Eur Stroke J. 2019;4(2):160-171.  https://doi.org/10.1177/2396987318825484
  17. Sweeney MD, Montagne A, Sagare AP. Vascular dysfunction — The disregarded partner of Alzheimer’s disease. Alzheimer’s Dement. 2019;15:158-6.  https://doi.org/10.1016/j.jalz.2018.07.222
  18. Bogolepova A. N. Sovremennaja koncepcija smeshannoj demencii. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2015;115(5):120-126. (In Russ.). https://doi.org/10.17116/jnevro201511551120-126
  19. Moroni F, Ammirati E, Rocca MA, et al. Cardiovascular disease and brain health: Focus on white matter hyperintensities. Int J Cardiol Heart Vasc. 2018;19:63-69.  https://doi.org/10.1016/j.ijcha.2018.04.006
  20. Vasquez BP, Zakzanis KK. The neuropsychological profile of vascular cognitive impairment not demented: a meta-analysis. J Neuropsychol. 2015;9(1):109-136.  https://doi.org/10.1111/jnp.12039
  21. De Bruijn RFAG., Bos MJ., Portegies MLP. The potential for prevention of dementia across two decades: the prospective, population based Rotterdam Study. BMC Med. 2015;13:132. 
  22. Barnes JN. Exercise, cognitive function, and aging. Adv Physiol Educ. 2015; 39(2):55-62.  https://doi.org/10.1152/advan.00101.2014
  23. Wu L, Sun D. Adherence to Mediterranean diet and risk of developing cognitive disorders: an updated systematic review and meta-analysis of prospective cohort studies. Sci Rep. 2017;7: 41317. https://doi.org/10.1038/srep41317
  24. Gorelick PB. The global burden of stroke: persistent and disabling. The Lancet Neurology. 2019;18(5):417–418. 
  25. Jin BR., Liu HY. Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis. Neural Regen Res. 2019;14:805-16. 
  26. Herrmann N, Lanctot KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther. 2013;5(1):5. doi: 10.1186/alzrt201. https://doi.org/10.1186/alzrt201
  27. Chen N, Yang M, Guo J. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2013;1:CD008900. https://doi.org/10.1002/14651858.
  28. Zhang H-F, Huang L-B, Zhong Y-B. An overview of systematic reviews of Ginkgo biloba extracts for mild cognitive impairment and dementia. Front Aging Neurosci. 2016;8:276.  https://doi.org/10.3389/fnagi.2016.00276
  29. Guekht A, Skoog I, Edmundson S, Zakharov V, Korczyn AD. ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment. Stroke. 2017;48(5):1262–1270. https://doi.org/10.1161/STROKEAHA.116.014321
  30. Cotroneo AM, Castagna A, Putignano S, Lacava R, Fantò F, Monteleone F, Rocca F, Malara A, Gareri P. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin Interv Aging. 2013;8:131-7. doi: 10.2147/CIA.S38420. https://doi.org/10.2147/CIA.S38420
  31. Instructions for the medical use of the drug Prospecta. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=9d0e194c-8255-403f-abf0-dc58b18c241d&t=
  32. Belova AN, Bogdanov EI, Voznyuk IA, Zhdanov VA, Kamchatnov PR, Kurushina OV, Maslova NN. Terapiya umerennykh kognitivnykh rasstroystv v rannem vosstanovitel’nom periode ishemicheskogo insul’ta. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2021;121(5):26–32.  https://doi.org/10.17116/jnevro202112105126
  33. Azimova YuE, Tabeyeva GR. Effektivnost’ preparata Memorel’ i obshcheprinyatykh skhem lecheniya kognitivnykh narusheniy: rezul’taty obshcherossiyskoy otkrytoy sravnitel’noy mnogotsentrovoy nablyudatel’noy 6-mesyachnoy programmy. Lechebnoye delo. 2016;4:57–63. 
  34. Yakhno NN, Zakharov VV, Strachunskaya EYa. i dr. Lecheniye nedementnykh kognitivnykh narusheniy u patsiyentov s arterial’noy gipertenziyey i tserebral’nym aterosklerozom (po dannym rossiyskogo mul’titsentrovogo issledovaniya «FUETE»). Nevrologicheskiy zhurnal. 2012;17(4):49–55. 
  35. Raskurazhev A.A., Naminov A.V., Kuznetsov P.I. Kompleksnaya terapiya rasstroystv pamyati sosudistogo geneza. Nevrologiya. 2017;3(3): 32–34. 
  36. Bogolepova AN, Burd SG, Lebedeva AV, Kovalenko YeA. Opyt primeneniya tsitikolina u patsiyentov s postinsul’tnymi kognitivnymi narusheniyami. Nevrologiya, neyropsikhiatriya, psikhosomatika. 2020;12(4):43–48.  https://doi.org/10.14412/2074-2711-2020-4-43-48.
  37. RCT No. 440 (09.08.2019) https://grls.rosminzdrav.ru/CIPermissionMini.aspx?CIStatementGUID=39549e32-228a-4f18-8bfa-3930c2b33b40&CIPermGUID=F8B0143E-8220-4E50-92AD-B5DB9EB7F671
  38. RCT No. 437 (21.08.2020) https://grls.rosminzdrav.ru/CIPermissionMini.aspx?CIStatementGUID=2a752549-ee50-43d9-94e8-1535f435e81c&CIPermGUID=FA2F744C-611A-42E0-AB88-13262CE44B5C
  39. RCT No. 335 (17.07.2020) https://grls.rosminzdrav.ru/CIPermissionMini.aspx?CIStatementGUID=9db22fb1-9275-42db-825c-99c786534731&CIPermGUID=F7BD86AB-384C-4A15-8345-F7E7DEFDCC03
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.